A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration

Trial Profile

A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2015

At a glance

  • Drugs Tesidolumab (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 15 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Jan 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 May 2018 to 1 Jun 2015.
    • 13 Jan 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 May 2018 to 1 Jun 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top